Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: diffuse systemic sclerosis

Case Report: MPA Hiding in Plain Sight

Benjamin Aronow, MD, Eduardo Mantovani Cardoso, MD, Steffi Thomas, DO, Prashant Grover, MD, & Weishali Joshi, MD  |  May 12, 2022

The COVID-19 pandemic has filled hospitals with patients with rapidly progressive respiratory failure and diffuse bilateral opacities on chest X-ray.1 Additionally, many patients with severe COVID-19 develop acute kidney injury and require dialysis.2 Pulmonary-renal syndromes are also important to consider in this setting. Although alveolar hemorrhage is a cardinal feature of this syndrome, many patients…

Filed under:ConditionsVasculitis Tagged with:AAV FocusRheumcase reportCOVID-19Fellowsmicroscopic polyangiitis (MPA)Polyangiitis

The Ins & Outs of ILD: The Management & Treatment of ILD in Patients with Rheumatic Disease

Lara C. Pullen, PhD  |  February 2, 2022

Melissa Griffith, MD, discussed the diagnosis and treatment of interstitial lung disease (ILD) in patients with rheumatic diseases, including connective tissue disease and more.

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2021connective tissue diseaseILDinterstitial lung disease (ILD)pneumoniaRheumatoid Arthritis (RA)Sclerodermascleroderma-associated ILD

In the Thick of It: Scleroderma Update 2021

Jason Liebowitz, MD, FACR  |  December 2, 2021

Laura Hummers, MD, MSc, provided an update on the extra-pulmonary manifestations of scleroderma & the best ways to approach management of these issues.

Filed under:ACR ConvergenceConditionsMeeting ReportsSystemic Sclerosis Tagged with:ACR Convergence 2021

Advances in Connective Tissue Disease-Associated Interstitial Lung Disease

Jason Liebowitz, MD, FACR  |  December 1, 2021

ACR Convergence 2021—The past year has been an exciting time for researchers and clinicians focused on the topic of connective tissue disease-associated interstitial lung disease (CTD-ILD), with advances in our understanding of these disorders and newly approved medications for their treatment. At the ACR Convergence 2021 annual Review Course, Kristin Highland, MD, MSCR, director of…

Filed under:ACR ConvergenceConditionsMeeting ReportsSystemic Sclerosis Tagged with:ACR Convergence 2021connective tissue diseaseinterstitial lung disease (ILD)nintedanib

Regressed germinal center with follicular dendritic cell prominence (star), onion-skinning (blue arrowhead) and increased vascularity (orange arrows) are seen.

Case Report: Is It Castleman Disease, or Castleman-Like?

Philip Chu, MD, RhMSUS, Mithu Maheswaranathan, MD, Jadee L. Neff, MD, PhD, & Rebecca E. Sadun, MD, PhD  |  October 13, 2021

The difference between Castle­man disease and Castleman-like disease may be subtle, but it comes with significant ramifications. Case Presentation This case involves a pregnant 19-year-old woman who presents over multiple hospitalizations with concerns for systemic lupus erythematosus and macrophage activation syndrome. At 36 weeks’ gestation, the patient’s weight had dropped from 215 lbs. to 170…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:case reportCastleman's disease

Tocilizumab Effective for Early SSc-Associated Interstitial Lung Disease

Lara C. Pullen, PhD  |  September 22, 2021

Treatment with tocilizimab preserved lung function in patients with systemic sclerosis (SSc) and interstitial lung disease (ILD) regardless of a patient’s level of lung involvement, according to a recent study.

Filed under:Conditions Tagged with:interstitial lung disease (ILD)systemic sclerosis (SSc)systemic sclerosis-associated ILDtocilizumab

Myositis & the Heart: New Perspectives on the Pathogenesis & Management of Cardiac Involvement in Myositis

Carina Stanton  |  February 18, 2021

Experts discuss the diagnosis and treatment of myositis-related cardiovascular disease.

Filed under:ACR ConvergenceConditionsMeeting ReportsMyositis Tagged with:ACR Convergence 2020cardiovascularheartHeart Diseasemyocarditismyositis

Case Report: Drug-Induced Lupus & ANCA-Associated Vasculitis Overlap

Mohammad A. Ursani, MD, RhMSUS, Ojas Naik, MD, Rohaan Khan & William F. Glass II, MD, PhD  |  February 16, 2021

Drug-induced lupus erythe­matosus and ANCA-associated vasculitis (AAV) are both autoimmune conditions associated with the use of hydralazine, a commonly prescribed drug for hypertension and congestive heart failure. Although the pathogenesis is unknown, it is believed that hydralazine alters neutrophil and lymphocyte function and promotes exposure of antigens, leading to the development of anti-neutrophil antibodies (ANCA)…

Filed under:ConditionsSystemic Lupus ErythematosusVasculitis Tagged with:ANCA-Associated Vasculitiscase reporthydralazine

Lost and found

The History of ACE Inhibitors in Scleroderma Renal Crisis

Ruth Jessen Hickman, MD  |  February 16, 2021

Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

Filed under:ConditionsSystemic Sclerosis Tagged with:Lost & FoundRenal disease

Late-Breaking Abstract Session Spans the Realm of Drug-Related Research

Vanessa Caceres  |  January 25, 2021

In the late-breaking abstract session at ACR Convergence 2020, drug research for a variety of indications is reviewed.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2020diffuse cutaneous systemic sclerosisgiant cell arteritis (GCA)mavrilimumabtocilizumabTofacitinibVIG7734Ziritaxestat

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 11
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences